With a market cap of $11.7 billion, DaVita Inc. (DVA) provides kidney dialysis and related laboratory services for patients with chronic kidney failure, primarily through outpatient centers. It also offers integrated care, clinical research, physician services, and comprehensive kidney care, including home-based and hospital dialysis options.
Shares of the Denver, Colorado-based company have surpassed the broader market over the past 52 weeks. DVA stock has soared 43.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 21.7%. Moreover, the stock has climbed 62.8% on a YTD basis, compared to SPX's 13.3% rise.